[{"Assets_0_Q2_USD":254547000.0,"EarningsPerShareBasic_2_Q2_USD":0.27,"EarningsPerShareBasic_1_Q2_USD":0.12,"EarningsPerShareDiluted_1_Q2_USD":0.12,"EarningsPerShareDiluted_2_Q2_USD":0.27,"NetIncomeLoss_2_Q2_USD":11590000.0,"NetIncomeLoss_1_Q2_USD":5288000.0,"PaymentsOfDividendsCommonStock_2_Q2_USD":10577000.0,"StockholdersEquity_0_Q2_USD":174336000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":42732000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":42693000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":42289000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":42323000.0,"Ticker":"VIVO","CIK":"794172","name":"MERIDIAN BIOSCIENCE INC","OfficialName":"Meridian Bioscience Inc. Common Stock","form":"10-Q","period":"20180331","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1192599275.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20180510"}]